Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 24, 2024
Politics, Policy & Law
Pediatric PRVs, Biosecure & Novo’s obesity miss: a BioCentury podcast
Misunderstandings on priority review vouchers in Congress. A door closes for Biosecure. Setback for Novo Nordisk
BioCentury | Sep 20, 2024
Product Development
Novo’s Phase II miss in obesity oral amps up pressure on BD
Ph II data from CB1 blocker monlunabant show poor weight loss at 16 weeks, plus neuropsychiatric adverse events
BioCentury | Jun 11, 2024
Product Development
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout
Plus: Bluejay, Vir give HDV updates; Skye’s miss in glaucoma; and more
BioCentury | Apr 12, 2024
Finance
Public equity report: Acrivon refreshes balance sheet with $130M PIPE
Plus Eliem, Century raise private placements as they make acquisitions; Nurix’s AACR readout precedes follow-on; Skye uplists
BioCentury | Nov 10, 2023
Data Byte
AstraZeneca-Eccogene among largest obesity deals year-to-date
AZ tries again in GLP-1 space, as Lilly and Novo deals this year show push into new mechanisms
BioCentury | Aug 22, 2023
Deals
Why 5AM and Versant forged a deal to unite two cannabinoid companies
With interest in CB1 on the rise, the longtime backers of Bird Rock saw a path forward by joining its asset with Skye’s
BioCentury | Aug 22, 2023
Regulation
Aug. 21 Quick Takes: Pfizer’s Abrysvo granted maternal indication
Plus: Andreessen Horowitz co-leads $200M round for AI company Genesis, Leqembi closes in on Japan approval and more
BioCentury | Aug 11, 2023
Deals
Novo’s Inversago takeout brings another appetite and glucose modulator to its obesity arsenal
Inversago’s program was geared to revive CB1 receptor as a metabolic target by avoiding the central nervous system
BioCentury | Oct 20, 2022
Deals
Oct. 19 Quick Takes: ‘Dark genome’ autoimmunity play Nucleome raises £37.5M series A
Plus venture rounds for Orionis, PIC, Inversago; PTC slips after pausing Huntington trial and more
BioCentury | Jun 9, 2021
Product Development
June 8 Quick Takes: FDA approves Prevnar 20; plus Bayer’s BlueRock, Innovent-IASO, Strateos, Aclaris, Incyte and more
CDC’s Advisory Committee on Immunization Practices (ACIP) will meet in October to discuss and update recommendations on adult immunizations with pneumococcal vaccines including Prevnar 20 from
Items per page:
1 - 10 of 21